Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance. The alliance seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers. Kymouse™, Kymab’s human antibody…